Selegiline hydrochloride and cognition
- 1 October 1991
- journal article
- review article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 84 (S136) , 91-94
- https://doi.org/10.1111/j.1600-0404.1991.tb05027.x
Abstract
Selegiline HCl, 10 mg per day has been reported to improve attention and episodic memory in Parkinson's disease and early Alzheimer's disease. Selegiline also improves motor reaction times in Parkinson's and subjective feelings of increased vitality, euphoria and energy. At doses of between 10 and 40 mg a day it has also been shown to improve depression particularly when psychomotor retardation is prominent and anxiety minimal.Keywords
This publication has 20 references indexed in Scilit:
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- New approaches in the use of selegiline for the treatment of Parkinson's diseaseActa Neurologica Scandinavica, 1989
- BRADYPHRENIA IN PARKINSON'S DISEASE AND PSYCHOMOTOR RETARDATION IN DEPRESSIVE ILLNESSBrain, 1987
- Tyramine pressor sensitivity changes during deprenyl treatmentPsychopharmacology, 1985
- The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatmentActa Neurologica Scandinavica, 1983
- Deprenyl in Parkinson diseaseNeurology, 1981
- Deprenyl is metabolized to methamphetamine and amphetamine in man.Published by Wiley ,1978
- The possible mechanisms of action of (-)deprenyl in Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978
- Phenylethylamine: evidence for a direct, postsynaptic dopamine-receptor stimulating actionBrain Research, 1977
- The effect of β-phenylethylamine on central and peripheral monoamine-containing neuronsEuropean Journal of Pharmacology, 1967